Annals of Oncology Advance Access originally published online on April 26, 2006
Annals of Oncology 2006 17(7):1096-1102; doi:10.1093/annonc/mdl081
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study
1 US Oncology Research, Inc., Houston, TX; 2 Oncology/Hematology Care Inc, Cincinnati, OH, USA; 3 Academish Ziekenhuis Nijmegen St. Raboud, Nijmegen, the Netherlands; 4 University Hospitals of Cleveland, Ireland Cancer Center, Cleveland, OH; 5 University of South Florida, Tampa FL; 6 Pfizer Global Research and Development, Ann Arbor, MI, USA
* Correspondence to: Dr D. A. Richards, US Oncology Research, Tyler Cancer Center, 910 E. Houston Street, Suite 100, Tyler, Texas 75702, USA. Tel: +1-903-579-9800; Fax: +1-903-579-9935; E-mail: Donald.Richards{at}USOncology.com
Background: CI-994, an oral histone deacetylase inhibitor, has antineoplastic activity and synergism with gemcitabine preclinically. This randomized phase II trial explored whether CI-994 plus gemcitabine improves overall survival, objective response, duration of response, time to treatment failure and change in quality of life (QoL) or pain compared with gemcitabine alone.
Patients and methods: A total of 174 patients received CG (CI-994 6 mg/m2/day days 1–21 plus gemcitabine 1000 mg/m2 days 1, 8 and 15 each 28-day cycle) or PG (placebo plus gemcitabine 1000 mg/m2 days 1, 8 and 15 of each 28-day cycle days 1–21).
Results: Median survival was 194 days (CG) versus 214 days (PG) (P = 0.908). The objective response rate with CG was 12% versus 14% with PG when investigator-assessed and 1% versus 6%, respectively, when assessed centrally. Time to treatment failure did not differ between the two arms (P = 0.304). QoL scores at 2 months were worse with CG than with PG. Pain response rates were similar between the two groups. There was an increased incidence of neutropenia and thrombocytopenia with CG.
Conclusions: Adding CI-994 to gemcitabine in advanced pancreatic carcinoma does not improve overall survival, response rate or time to progression; CG produced decreased QoL and increased hematological toxicity and appears inferior to single-agent gemcitabine.
Key words: gemcitabine, histone deacetylation inhibitor, metastatic disease, pain, pancreatic cancer, placebo, quality of life
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Garcia-Manero, S. Assouline, J. Cortes, Z. Estrov, H. Kantarjian, H. Yang, W. M. Newsome, W. H. Miller Jr, C. Rousseau, A. Kalita, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood, August 15, 2008; 112(4): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Bernhard, D. Dietrich, W. Scheithauer, D. Gerber, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schuller, P. Saletti, et al. Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial--SAKK 44/00-CECOG/PAN.1.3.001 J. Clin. Oncol., August 1, 2008; 26(22): 3695 - 3701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Krueger and S. Srivastava Posttranslational Protein Modifications: Current Implications for Cancer Detection, Prevention, and Therapeutics Mol. Cell. Proteomics, October 1, 2006; 5(10): 1799 - 1810. [Full Text] [PDF]
|
|